Evidence map›Paper›PMID 39691396›Full record

ReviewFrontiers in pharmacology2024

Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.

Yilin Su, Lisha Liu, Chongyang Lin, Dashi Deng, Yunfei Li, Mou Huang, Yu Wang, Kangqiu Ling, Haobing Wang, Qiyu Chen and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yilin Su *Institute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Lisha Liu *Institute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Chongyang LinInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Dashi DengInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Yunfei LiInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Mou HuangInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Yu WangInstitute of Pain, The Affiliated Hospital of Southwest Jiaotong University, The Chengdu Third People's Hospital, Chengdu, China.
Kangqiu LingInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Haobing WangInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Qiyu ChenInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Guixiao HuangInstitute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oridonin (ORI), an ent-kaurane diterpenoid derived from Rabdosia rubescens (Hemsl.) H.Hara, serves as the primary bioactive component of this plant. It demonstrates a broad spectrum of therapeutic activities, including moderate to potent anticancer properties, alongside anti-inflammatory, antibacterial, antifibrotic, immunomodulatory, and neuromodulatory effects, thus influencing diverse biological processes. However, its clinical potential is significantly constrained by poor aqueous solubility and limited bioavailability. In alignment with the approach of developing drug candidates from natural compounds, various strategies, such as structural modification and nanocarrier systems, have been employed to address these challenges. This review provides an overview of ORI-based nano-delivery systems, emphasizing their potential to improve the clinical applicability of oridonin in oncology. Although some progress has been made in advancing ORI nano-delivery research, it remains insufficient for clinical implementation, necessitating further investigation.

Indexed as

antitumorcarrierdrug delivery systemnanoparticleoridonin

Identifiers

PMID39691396
PMCPMC11649421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.